TEYSUNO™ (S-1) IS BENEFICIAL FOR EGFR-TKI REFRACTORY NSCLC PATIENTS

This study is to explore Teysuno™ (S-1), an oral fixed-dose combination of three active substances, in the treatment of Non-small-cell lung carcinoma.Twenty-four patients with advanced NSCLC were recruited and were treated with salvage therapy with orally administered Teysuno capsules. Treatment was followed by one week of rest before the second cycle. The response and side effects are observed after two cycles of therapy. Two patients showed partial response, ten showed stable disease, twelve showed progressive disease and none showed complete response. The objective response rate was 8.3% and the disease control rate was 50.0%. Disease control rate and progression-free survival were higher in patients who had previously received at least six months of EGFR-TKI therapy. All side effects were considered tolerable, and no fatalities were associated with the therapy.In conclusion: Teysuno is an effective treatment strategy for EGFR-TKI refractory NSCLC patients, providing a novel therapeutic option for these patients.